Meiact

Meiact Dosage/Direction for Use

cefditoren

Manufacturer:

Meiji Seika Pharma

Distributor:

DKSH

Marketer:

Medreich
Full Prescribing Info
Dosage/Direction for Use
See Indications for indicated pathogens. (See Table 3.)

Click on icon to see table/diagram/image

Patients with Renal Insufficiency: No dose adjustment is necessary for patients with mild renal impairment (CLcr: 50-80 mL/min/1.73 m2). It is recommended that not more than 200 mg BID be administered to patients with moderate renal impairment (CLcr: 30-49 mL/min/1.73 m2) and 200 mg QD be administered to patients with severe renal impairment (CLcr: <30 mL/min/1.73 m2).
The appropriate dose in patients with end-stage renal disease has not been determined.
Patients with Hepatic Disease: No dose adjustments are necessary for patients with mild or moderate hepatic impairment (Child-Pugh Class A or B). The pharmacokinetics of cefditoren have not been studied in patients with severe hepatic impairment (Child-Pugh Class C).
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in